Table 2 Adverse events (grade 3/4).

From: Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

AE (grade 3/4)

ET N = 31 n (%)

CT N = 100 n (%)

Leukopenia

0

17 (17)

Thrombocytopenia

0

3 (3)

Anorexia

0

2 (2)

Anemia

1 (3.2)

1 (1)

Palmar-plantar erythrodysesthesia syndrome

0

1 (1)

Atrial fibrillation

0

1 (1)

Alanine aminotransferase increased

0

1 (1)

Pneumonitis

1 (3.2)

1 (1)

Oral mucositis

1 (3.2)

0

All

3 (9.6)

27 (27)